Clinical Trials Browser

Has results × Prostatic Neoplasms × Paclitaxel × Clear all

NCT02711137 2025-10-21

Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies

Phase 1/2 Terminated

137 enrolled 31 charts

BreastCNSGastrointestinalGenitourinaryGynecologicLymphoidMyeloidOther hematologic neoplasmPlasma cellThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Glioblastoma, Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Lymphoma, Large B-Cell, Diffuse, Primary Myelofibrosis

NCT04221828 2022-03-29

Trial of NanoPac Focal Therapy for Prostate Cancer

Phase 2 Terminated

1 enrolled 5 charts

Genital Neoplasms, Male, Prostatic Neoplasms, Urogenital Neoplasms

NCT00004054 2020-10-22

Hormone Therapy Plus Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Prostate Cancer

Phase 3 Completed

397 enrolled 11 charts

Prostatic Neoplasms

NCT00049257 2020-09-01

Paclitaxel and Carboplatin in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy

Phase 2 Completed

58 enrolled 9 charts

Prostatic Neoplasms

NCT01558492 2017-06-09

Carboplatin and Paclitaxel in Patients With Metastatic, Castrate-Resistant Prostate Cancer

Phase 2 Terminated

3 enrolled 3 charts

Prostatic Neoplasms

NCT00016913 2016-07-06

Chemotherapy, Hormone Therapy, and Radiation Therapy in Treating Patients With Locally Advanced Prostate Cancer

Phase 2 Completed

34 enrolled 5 charts

Prostatic Neoplasms

NCT00028769 2013-07-16

S0032, Combination Chemotherapy Plus Hormone Therapy in Treating Patients With Metastatic Prostate Cancer

Phase 2 Completed

41 enrolled 12 charts

Prostatic Neoplasms